Camibirstat
FHD-286 is a selective, oral inhibitor of SMARCA4/SMARCA2 ATPase (BRG1 and BRM) inhibitor. FHD-286 has the potential for the research of BAF (BRG1/BRM-associated factor) -related disorders such as acute myeloid leukemia[1].
Product Specifications
CAS Number
2671128-05-3
Product Name Alternative
FHD-286
UNSPSC
12352005
Target
Epigenetic Reader Domain; Oxidative Phosphorylation
Type
Reference compound
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/fhd-286.html
Purity
99.06
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
COC[C@@H](C(NC1=NC(C2=CC=CC(N3C[C@@H](O[C@@H](C3)C)C)=N2)=CS1)=O)NC(C4=CN(C=C4)S(C)(=O)=O)=O
Molecular Formula
C24H30N6O6S2
Molecular Weight
562.66
References & Citations
[1]Warren C. Fiskus, et al. Abstract 1140: Pre-clinical efficacy of targeting BAF complexes through inhibition of the dual ATPases BRG1 and BRM by FHD-286 in cellular models of AML. Cancer Res (2023) 83 (7_Supplement) : 1140.|[2]Kana Ichikawa, et al. Synergistic efficacy of the BRM/BRG1 ATPase inhibitor, FHD-286, and anti-PD-1 antibody in mouse syngeneic tumor models.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC941820-100 1x 100 µL
Ep-CAM / CD326 (Epithelial Marker) (rVU-1D9), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC472216-100 1x 100 µL
CD50 / ICAM3 (CG106), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 